Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Iowa City, IA
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Boston, MA
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Bronx, NY
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Durham, NC
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Richmond, VA
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated:  1/26/2016
Research site
mi
from
San Juan,
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)
Status: Enrolling
Updated: 1/26/2016
Research site
mi
from
San Juan,
Click here to add this to my saved trials
Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics
Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/27/2016
Sisters of Charity Hospital
mi
from
Buffalo, NY
Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics
Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/27/2016
Sisters of Charity Hospital
mi
from
Buffalo, NY
Click here to add this to my saved trials
Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics
Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/27/2016
Synergy Bariatrics
mi
from
Williamsville, NY
Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics
Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/27/2016
Synergy Bariatrics
mi
from
Williamsville, NY
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Aurora, CO
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Boston, MA
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Rochester, MN
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated:  1/27/2016
mi
from
Newtown,
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Status: Enrolling
Updated: 1/27/2016
mi
from
Newtown,
Click here to add this to my saved trials
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers
Status: Enrolling
Updated:  1/27/2016
Avail Clinical Research
mi
from
DeLand, FL
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers
Status: Enrolling
Updated: 1/27/2016
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers
Status: Enrolling
Updated:  1/27/2016
University of Miami
mi
from
Miami, FL
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers
Status: Enrolling
Updated: 1/27/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers
Status: Enrolling
Updated:  1/27/2016
Orlando Clinical Research Center
mi
from
Orlando, FL
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers
Status: Enrolling
Updated: 1/27/2016
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy
An Observer-blinded, Dose-finding Study to Investigate the Safety, Efficacy, and Patient Preference of Lactulose for Oral Solution With Bisacodyl for Cleansing of the Colon as a Preparation for Colonoscopy in Adults
Status: Enrolling
Updated:  1/27/2016
ClinSearch, LLC
mi
from
Chattanooga, TN
Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy
An Observer-blinded, Dose-finding Study to Investigate the Safety, Efficacy, and Patient Preference of Lactulose for Oral Solution With Bisacodyl for Cleansing of the Colon as a Preparation for Colonoscopy in Adults
Status: Enrolling
Updated: 1/27/2016
ClinSearch, LLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2
Rapid Opiate Detoxification & Naltrexone Induction Using Bup.
Status: Enrolling
Updated:  1/27/2016
Friends Research Institute
mi
from
Los Angeles, CA
Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2
Rapid Opiate Detoxification & Naltrexone Induction Using Bup.
Status: Enrolling
Updated: 1/27/2016
Friends Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Fish Oil to Reduce ALT Levels in Adolescents
Randomized Trial of Fish Oil Versus Placebo to Reduce ALT Levels in Overweight Adolescents
Status: Enrolling
Updated:  1/28/2016
Boston University Medical Center
mi
from
Boston, MA
Study of Fish Oil to Reduce ALT Levels in Adolescents
Randomized Trial of Fish Oil Versus Placebo to Reduce ALT Levels in Overweight Adolescents
Status: Enrolling
Updated: 1/28/2016
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
Doppler Ultrasound Probe for Blood Flow Detection in Severe UGI Bleed
Status: Enrolling
Updated:  1/28/2016
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
Doppler Ultrasound Probe for Blood Flow Detection in Severe UGI Bleed
Status: Enrolling
Updated: 1/28/2016
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
Doppler Ultrasound Probe for Blood Flow Detection in Severe UGI Bleed
Status: Enrolling
Updated:  1/28/2016
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
Doppler Ultrasound Probe for Blood Flow Detection in Severe UGI Bleed
Status: Enrolling
Updated: 1/28/2016
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.
Status: Enrolling
Updated:  1/28/2016
Sharp Healthcare
mi
from
San Diego, CA
Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.
Status: Enrolling
Updated: 1/28/2016
Sharp Healthcare
mi
from
San Diego, CA
Click here to add this to my saved trials
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
Status: Enrolling
Updated:  1/28/2016
GI Associates
mi
from
Milwaukee, WI
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
Status: Enrolling
Updated: 1/28/2016
GI Associates
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
Status: Enrolling
Updated:  1/28/2016
Medical College of Wisconsin
mi
from
Milwaukee, WI
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
Status: Enrolling
Updated: 1/28/2016
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
The Scripps Research Institute
mi
from
LaJolla, CA
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
The Scripps Research Institute
mi
from
LaJolla, CA
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
University of Maryland Medical Center
mi
from
Baltimore, MD
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
Syosset Hospital
mi
from
Lake Success, NY
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
Syosset Hospital
mi
from
Lake Success, NY
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
Rhode Island Hospital
mi
from
Providence, RI
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Wiser Choices in Osteoporosis Choice II: A Decision Aid for Patients and Clinicians
Wiser Choices In Osteoporosis Choice II
Status: Enrolling
Updated:  2/1/2016
The Mayo Clinic
mi
from
Rochester, MN
Wiser Choices in Osteoporosis Choice II: A Decision Aid for Patients and Clinicians
Wiser Choices In Osteoporosis Choice II
Status: Enrolling
Updated: 2/1/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Effects of Ibudilast (MN-166, Formerly AV411), a Glial Activation Inhibitor, on Oxycodone Self-administration in Opioid Abusers
Status: Enrolling
Updated:  2/1/2016
New York State Psychiatric Institute
mi
from
New York, NY
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Effects of Ibudilast (MN-166, Formerly AV411), a Glial Activation Inhibitor, on Oxycodone Self-administration in Opioid Abusers
Status: Enrolling
Updated: 2/1/2016
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated:  2/1/2016
Ahuja/University Hospitals
mi
from
Beachwood, OH
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated: 2/1/2016
Ahuja/University Hospitals
mi
from
Beachwood, OH
Click here to add this to my saved trials
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated:  2/1/2016
Columbia University
mi
from
New York, NY
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated: 2/1/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated:  2/1/2016
Medical University of South Carolina
mi
from
Charleston, SC
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated: 2/1/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated:  2/1/2016
University of Maryland
mi
from
Baltimore, MD
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated: 2/1/2016
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated:  2/1/2016
University of North Carolina, Chapel Hill
mi
from
Chapel Hil, NC
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated: 2/1/2016
University of North Carolina, Chapel Hill
mi
from
Chapel Hil, NC
Click here to add this to my saved trials
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated:  2/1/2016
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy ("DOSE" Trial)
Status: Enrolling
Updated: 2/1/2016
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Little Rock, AR
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Duarte, CA
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Loma Linda, CA
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Denver, CO
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Atlanta, GA
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Chicago, IL
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Maywood, IL
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Maywood, IL
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Baltimore, MD
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Boston, MA
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials